Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.59 |
| ▸ | BACE1 | P56817 | 9/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237394 | 0.95 | NAALAD2 (0.64) | NAALAD2BACE1POLBLTA4HSLC15A1 | |
| SCHEMBL27652943 | 0.95 | NAALAD2 (0.64) | NAALAD2BACE1POLBLTA4HSLC15A1 | |
| SCHEMBL5970501 | 0.94 | NAALAD2 (0.55) | NAALAD2POLBLTA4HSLC15A1GNPAT | |
| SCHEMBL31672244 | 0.94 | NAALAD2 (0.55) | NAALAD2POLBLTA4HSLC15A1GNPAT | |
| SCHEMBL2487636 | 0.94 | NAALAD2 (0.55) | NAALAD2POLBLTA4HSLC15A1GNPAT | |
| SCHEMBL29743321 | 0.94 | NAALAD2 (0.55) | NAALAD2POLBLTA4HSLC15A1GNPAT | |
| SCHEMBL31094953 | 0.93 | NAALAD2 (0.60) | NAALAD2BACE1GNPATCTSD | |
| SCHEMBL29652313 | 0.93 | NAALAD2 (0.54) | NAALAD2BACE1GNPATMMEECE1 | |
| SCHEMBL6236774 | 0.92 | NAALAD2 (0.68) | NAALAD2POLBLTA4HSLC15A1GNPAT | |
| SCHEMBL3048911 | 0.92 | NAALAD2 (0.68) | NAALAD2POLBLTA4HSLC15A1GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016959-A1 | BIOLOGICALLY ACTIVE PEPTIDES COMPRISING PHENYLALANYL-GLUTAMATE (FE) AND PHENYLALANYL-GLUTAMYL-GLUTAMATE (FEE) | PEPHARM R & D LIMITED (CN) | 2005-02-24 | — | — | WO | claimed |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240207427-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230091653-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC. | 2023-03-23 | — | — | US | disclosed |
| CN-1930183-B | Bioactive peptides comprising phenylalanyl-glutamic acid and phenylalanyl-glutamyl-glutamic acid | PEPHARM R & D LTD | 2010-12-29 | — | — | CN | disclosed |
| CN-1930183-A | Bioactive peptides comprising phenylalanyl-glutamic acid and phenylalanyl-glutamyl-glutamic acid | PEPHARM R & D LTD (CN) | 2007-03-14 | — | — | CN | disclosed |
| WO-2005016959-A1 | BIOLOGICALLY ACTIVE PEPTIDES COMPRISING PHENYLALANYL-GLUTAMATE (FE) AND PHENYLALANYL-GLUTAMYL-GLUTAMATE (FEE) | PEPHARM R & D LIMITED (CN) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016959-A1 | BIOLOGICALLY ACTIVE PEPTIDES COMPRISING PHENYLALANYL-GLUTAMATE (FE) AND PHENYLALANYL-GLUTAMYL-GLUTAMATE (FEE) | PEPHARM R & D LIMITED (CN) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207427-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | NAALAD2 77/4885BACE1 654/4885POLB 2889/4885 |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | NAALAD2 77/4885BACE1 654/4885POLB 2889/4885 |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | CTSB, CTSE, CTSZ | NAALAD2 77/4885BACE1 654/4885POLB 2889/4885 |
| US-20230091653-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | NAALAD2 77/4885BACE1 654/4885POLB 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.